Publication & Citation Trends
Publications
0 total
IN VIVO CRISPR/CAS9 EDITING OF KLKB1 IN PATIENTS WITH HEREDITARY ANGIOEDEMA: A FIRST-IN-HUMAN STUDY
Cited by 13
Semantic Scholar
MO31-2 Telisotuzumab vedotin monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer OA
Cited by 0
Semantic Scholar
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial. OA
Cited by 143
Semantic Scholar
P47.03 Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer: Stage 2 OA
Cited by 1
Semantic Scholar
A Phase 1 – 2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC
Cited by 13
Semantic Scholar
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness OA
Cited by 26
Semantic Scholar
Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin OA
Cited by 9
Semantic Scholar
P60.12 Prevalence of c-Met overexpression (c-Met+) and Impact of Prior Lines of Treatment on c-Met Protein Expression in NSCLC OA
Cited by 6
Semantic Scholar
119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial OA
Cited by 17
Semantic Scholar
Research Topics
PARP inhibition in cancer therapy
(50)
Advanced Breast Cancer Therapies
(16)
Glioma Diagnosis and Treatment
(13)
Cancer Treatment and Pharmacology
(13)
RNA and protein synthesis mechanisms
(11)
Affiliations
Goethe University Frankfurt
Centre National de la Recherche Scientifique
Pennsylvania State University
Johns Hopkins University
Inserm